6月1日，宝济药业-B盘中下跌5.46%，报23.2港元/股，成交额4265.7万港元。
消息面上，公司此前获纳入MSCI全球指数成分股，于5月29日收市后正式生效，今日为生效后首个交易日。市场此前已有"入通即崩"现象反复上演的讨论，资金博弈预期兑现后出现获利了结压力。此外，生物科技板块今日整体承压，百济神州跌3.45%、科伦博泰生物跌6.8%、信达生物跌2.88%，行业系统性走弱加剧个股回调。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长落定、中邮证券首予"增持"评级，但市场信心仍处于修复阶段。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.